(Q35121715)

6 August 2017

1 reference

title

Management of multiple myeloma: a systematic review and critical appraisal of published studies (English)

1 reference

6 August 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01077-5

30 December 2023

5

Benjamin Djulbegovic

1 reference

6 August 2017

1

Ambuj Kumar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12732167

30 December 2023

4

Brian G. M. Durie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12732167

30 December 2023

author name string

Thomas Loughran

2

1 reference

6 August 2017

Melissa Alsina

3

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12732167

30 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S1470204503010775?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01077-5

https://api.elsevier.com/content/article/PII:S1470204503010775?httpAccept=text/plain

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01077-5

Lancet Oncology Commission

30 December 2023

published in

1 reference

6 August 2017

4

1 reference

6 August 2017

293-304

1 reference

6 August 2017

5

1 reference

Current therapy for multiple myeloma

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Identifying relevant studies for systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Evaluation and appraisal of randomized controlled trials in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

The Landscape and Lexicon of Blinding in Randomized Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

The quality of medical evidence in hematology-oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

The uncertainty principle and industry-sponsored research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Cyclophosphamide vs melphalan in treatment of plasma cell myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Randomized trial experience of the Intergroupe Francophone du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Thalidomide in the management of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Effect of daily etidronate on the osteolysis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Absence of evidence is not evidence of absence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901077-5

7 January 2021

Assessing the Quality of Randomised Controlled Trials

10

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01077-5

Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU

30 December 2023

43

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01077-5

Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma

30 December 2023

59

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01077-5

30 December 2023

Identifiers

1 reference

release_yr5hxk3dkvgpxb5h2l4f6zryze

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yr5hxk3dkvgpxb5h2l4f6zryze

24 November 2022

mapped directly with Wikidata item

1 reference